{"sourcedb":"DevicePMAs@therightstef","sourceid":"P150013_S000","text":"Approval for the pd-l1 ihc 22c3 pharmdx. this device is indicated for the following:  pd-l1 ihc 22c3 pharmdx is a qualitative immunohistochemical assay using monoclonal mouse anti-pd-l1, clone 22c3 antibody intended for use in the detection of pd-l1protein in formalin fixed, paraffin embedded (ffpe) non-small cell lung cancer (nsclc) tissue using envision flex visualization system on autostainer link 48. pd-l1 protein expression is determined by using tumor proportion score (tps), which is the percentage of viable tumor cells showing partial or complete membrane staining. the specimen should be considered pd-l1 positive if tps \u003E= 50% of the viable tumor cells exhibit membrane staining at any intensity. pd-l1 ihc 22c3 pharmdx is indicated as an aid in identifying nsclc patients for treatment with keytruda (pembrolizumab).","project":"consensus_PMA_Age_Indications"}